Cargando…

Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study

INTRODUCTION: Clostridioides difficile infection (CDI) is associated with increased hospital stays and mortality and a high likelihood of rehospitalization, leading to increased health resource use and costs. The objective was to estimate the economic burden of recurrent CDI (rCDI). MATERIAL AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouza, Emilio, Cobo, Javier, Rodríguez-Hernández, Mª Jesús, Salavert, Miguel, Horcajada, Juan P, Iribarren, José Antonio, Obi, Engels, Lozano, Virginia, Maratia, Stefano, Cuesta, Maribel, Uría, Estefany, Limón, Enric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2021
Materias:	Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019457/ https://www.ncbi.nlm.nih.gov/pubmed/33618513 http://dx.doi.org/10.37201/req/135.2020

Ejemplares similares

Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR)
por: Bouza, Emilio, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
por: Salavert, Miguel, et al.
Publicado: (2018)

Treatment of Clostridioides difficile infection: from guidelines to clinical practice
por: Merino, Esperanza, et al.
Publicado: (2022)

Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non–C. difficile diarrhea, and C. difficile–colonized patients
por: Vázquez-Cuesta, Silvia, et al.
Publicado: (2023)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile—A Retrospective Observational Study
por: Deshpande, Abhishek, et al.
Publicado: (2022)

Clostridioides difficile infection epidemiology and clinical characteristics in COVID-19 pandemic
por: Vázquez-Cuesta, Silvia, et al.
Publicado: (2022)

Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection
por: Vázquez-Cuesta, Silvia, et al.
Publicado: (2023)

757. Evaluating Use of the New ICD-10 Codes for Clostridioides difficile Infection in the Premier U.S. Hospital Discharge Database
por: Deshpande, Abhishek, et al.
Publicado: (2021)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer
por: Francisco, Denise Marie A., et al.
Publicado: (2022)

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
por: Hengel, Richard L., et al.
Publicado: (2022)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
por: Dubberke, Erik R, et al.
Publicado: (2023)

Impact of a training program on the surveillance of Clostridioides difficile infection
por: Sopena, N., et al.
Publicado: (2019)

Iron Regulation in Clostridioides difficile
por: Berges, Mareike, et al.
Publicado: (2018)

Extraintestinal Clostridioides difficile infection
por: Hai, Zhao, et al.
Publicado: (2020)

Pathogenicity and virulence of Clostridioides difficile
por: Buddle, Jessica E., et al.
Publicado: (2023)

Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile
por: Suarez-Carantoña, Cecilia, et al.
Publicado: (2021)

Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
por: Ahn, Seung Woo, et al.
Publicado: (2021)

Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China
por: Cui, Yingchao, et al.
Publicado: (2019)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

Metabolism the Difficile Way: The Key to the Success of the Pathogen Clostridioides difficile
por: Neumann-Schaal, Meina, et al.
Publicado: (2019)

Clostridioides difficile therapeutics: guidelines and beyond
por: Orenstein, Robert, et al.
Publicado: (2019)

Impact of ribotype on Clostridioides difficile diagnostics
por: Rizzardi, Kristina, et al.
Publicado: (2019)

Clostridioides (Clostridium) difficile Pacemaker Infection
por: Berkefeld, Anna, et al.
Publicado: (2020)

Opportunities for Nanomedicine in Clostridioides difficile Infection
por: Wang, Pei-Wen, et al.
Publicado: (2021)

Introduction to the Special Issue on Clostridioides difficile
por: Granata, Guido, et al.
Publicado: (2021)

Epidemiology of Clostridioides difficile in South Africa
por: de Jager, Pieter, et al.
Publicado: (2021)

The repertoire of ABC proteins in Clostridioides difficile
por: Pipatthana, Methinee, et al.
Publicado: (2021)

An Update on Clostridioides difficile Binary Toxin
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2022)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

Phage therapy for Clostridioides difficile infection
por: Fujimoto, Kosuke, et al.
Publicado: (2022)

Clostridioides difficile, a New “Superbug”
por: Markovska, Rumyana, et al.
Publicado: (2023)

Editorial: Microbial interactions of Clostridioides difficile
por: Goh, Shan, et al.
Publicado: (2023)

Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention
por: Olmedo, María, et al.
Publicado: (2020)

15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S
por: Dubberke, Erik R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_su25366k3tkihig921ocgt0rvo